Kawada Junji, Mizuno Manatsu, Fukada Akio, Nakano Masaya, Murotani Masatoshi, Nagano Shinnosuke, Yoneda Naoki, Kidogami Shinya, Mokutani Yukako, Kishimoto Tomoya, Hashimoto Yasuji, Hirose Hajime, Yoshioka Shinichi, Tamura Shigeyuki, Sasaki Yo
Dept. of Surgery, Yao Municipal Hospital.
Gan To Kagaku Ryoho. 2022 Apr;49(4):462-464.
Chemotherapy-induced nausea and vomiting(CINV)are typical side effects caused by chemotherapy. We analyzed CINV during first-line chemotherapy for gastric cancer.
Thirty-one patients who received first-line chemotherapy for gastric cancer were retrospectively assessed for CINV.
The median age was 70 years, and the gender(male/female)was 23/8 cases. NK1 receptor antagonist, 5-HT3 receptor antagonist, and dexamethasone were used as antiemetic agents in 29 patients(94%). Sixteen patients(52%)had Grade 1 or higher nausea, and 6 patients (19%)had Grade 1 or higher vomiting, and complete control of nausea and vomiting was achieved in 21 patients(68%). Nausea was significantly more frequent in patients with liver metastasis(p=0.0008), but there was no significant difference in vomiting(p=1.0000). There was no significant difference in the occurrence of CINV between chemotherapy regimens or combination of olanzapine.
During first-line chemotherapy for gastric cancer, 3 antiemetic agents were used in 94% of cases, and the complete control rate of CINV was 67.8%.
化疗引起的恶心和呕吐（CINV）是化疗导致的典型副作用。我们分析了胃癌一线化疗期间的CINV情况。
对31例接受胃癌一线化疗的患者进行回顾性CINV评估。
中位年龄为70岁，性别（男/女）为23/8例。29例患者（94%）使用了NK1受体拮抗剂、5-HT3受体拮抗剂和地塞米松作为止吐药。16例患者（52%）出现1级或更高级别的恶心，6例患者（19%）出现1级或更高级别的呕吐，21例患者（68%）实现了恶心和呕吐的完全控制。肝转移患者的恶心发生率显著更高（p=0.0008），但呕吐发生率无显著差异（p=1.0000）。不同化疗方案或奥氮平联合使用之间CINV的发生率无显著差异。
在胃癌一线化疗期间，94%的病例使用了3种止吐药，CINV的完全控制率为67.8%。
